Lopinavir/r plus saquinavir — Competitive Intelligence Brief

Lopinavir/r plus saquinavir (Lopinavir/r plus saquinavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor combination. Area: Infectious Disease / Virology.

marketed HIV protease inhibitor combination HIV protease Infectious Disease / Virology Small molecule

Target snapshot

Lopinavir/r plus saquinavir (Lopinavir/r plus saquinavir) — The HIV Netherlands Australia Thailand Research Collaboration. This combination of two protease inhibitors blocks HIV protease to prevent viral replication, with ritonavir boosting lopinavir levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lopinavir/r plus saquinavir TARGET	Lopinavir/r plus saquinavir	The HIV Netherlands Australia Thailand Research Collaboration	marketed	HIV protease inhibitor combination	HIV protease
Maraviroc, Darunavir/r	Maraviroc, Darunavir/r	Catholic University of the Sacred Heart	marketed	Antiretroviral combination (CCR5 antagonist + protease inhibitor)	CCR5 co-receptor (maraviroc); HIV protease (darunavir)
atazanavir/tenofovir/emtricitabine	atazanavir/tenofovir/emtricitabine	Community Research Initiative of New England	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Darunavir/Ritonavir (Prezista)	Darunavir/Ritonavir (Prezista)	Kowa Research Institute, Inc.	marketed	HIV protease inhibitor	HIV protease
Reyataz + Epzicom	Reyataz + Epzicom	ViiV Healthcare	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Lopinavir/r	Lopinavir/r	Universidade Federal do Rio de Janeiro	marketed	Protease inhibitor	HIV protease
Symtuza® (TAF/FTC/DRV/c)	Symtuza® (TAF/FTC/DRV/c)	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (NRTI/INSTI class with protease inhibitor)	HIV reverse transcriptase, HIV protease, CYP3A4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor combination class)

1. Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · 1 drug in this class
2. Ottawa Hospital Research Institute · 1 drug in this class
3. The HIV Netherlands Australia Thailand Research Collaboration · 1 drug in this class
4. ViiV Healthcare · 1 drug in this class